# Ocrevus Zunovo

NDC: 50242-554
Generic name: ocrelizumab and hyaluronidase
Labeler / Manufacturer: Genentech, Inc.
Product type: HUMAN PRESCRIPTION DRUG
Marketing category: Biologic License Application
Dosage form: INJECTION, SOLUTION
Routes: SUBCUTANEOUS
Marketing started: 20240913

FDA application: BLA761371

## Active ingredients

- HYALURONIDASE (HUMAN RECOMBINANT): 23000 U/23mL
- OCRELIZUMAB: 920 mg/23mL

## Pharmacological class

—

## External sources

- openFDA: https://api.fda.gov/drug/ndc.json?search=product_ndc:"50242-554"
- FDA NDC Directory: https://www.accessdata.fda.gov/scripts/cder/ndc/dsp_searchresult.cfm?p_ndc=50242-554
- DailyMed: https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=b216af61-99d0-42a3-afc2-b5bf86df1ec0